15th Annual Perspectives in Thoracic Oncology

19. 11. 2010 - 20. 11. 2010, New York Marriott Downtown, New York, USA

Registrace

Friday, November 19, 2010

Session I: Introductory lectures

8:00 am
Welcome
Corey J. Langer, MD, FACP

8:10 am
Effects of tobacco on therapeutic outcome and prognosis: Rationale for treating tobacco dependence
Carolyn M. Dresler, MD

8:30 am
Lung cancer screening in 2010: Hope vs reality
James R. Jett, MD

8:50 am
Pathology: The critical issues in tissue acquisition and interpretation
Leslie A. Litzky, MD

9:10 am
Panel discussion and knowledge/confidence assessment of the audience via ARS survey

9:30 am
Break

Session II: Surgery and staging

9:50 am
Pre-activity knowledge/confidence assessment of the audience via ARS survey

9:55 am
The intricacies of staging in NSCLC
Gerard A. Silvestri, MD, MS

10:15 am
Restaging patients with stage IIIA NSCLC post-induction therapy: What is the optimal approach?
John C. Kucharczuk, MD

10:35 am
Debate: Surgery versus radiation therapy in marginally operable early stage NSCLC

Surgeon’s perspective: Speaker Invited

Radiation oncologist’s perspective: Jeffery D. Bradley, MD

11:05 am
Panel discussion and post-activity knowledge/confidence assessment of the audience via ARS survey

11:40 am
Luncheon Symposium
Supported by Lilly USA, LLC

Session III: Radiation oncology for the uninitiated and perpetually perplexed

12:55 pm
Pre-activity knowledge/confidence assessment of the audience via ARS survey

1:00 pm
Locally advanced unresectable NSCLC: State of the art and emerging therapies
Walter J. Curran, Jr., MD, FACR

1:20 pm
Stereotactic and image guided radiation therapy: Emerging role in localized lung cancer
Jeffery D. Bradley, MD

1:40 pm
The role of prophylactic cranial irradiation in SCLC and LA-NSCLC
Walter J. Curran, MD, FACR

2:00 pm
Panel discussion and post-activity knowledge/confidence assessment of the audience via ARS survey

Session IV: Adjuvant therapy

2:20 pm
Pre-activity knowledge/confidence assessment of the audience via ARS survey

2:25 pm
Adjuvant therapy: State of the art in 2010
Corey J. Langer, MD, FACP

2:55 pm
Ongoing clinical trials in the adjuvant arena
Tracey L. Evans, MD

3:15 pm
Panel discussion and post-activity knowledge/confidence assessment of the audience via ARS survey

3:35 pm
Break

Session V: Special topics in thoracic oncology

3:50 pm
Esophageal cancer: Therapeutic updates
David H. Ilson, MD

4:15 pm
SCLC: Challenges for an emerging orphan disease
Speaker Invited

4:40 pm
Revised classification of lung adenocarcinoma: What the clinician needs to know
Vincent A. Miller, MD

5:00 pm
Panel discussion and knowledge/confidence assessment of the audience via ARS survey

5:25 pm
Closing notes

5:30 pm
Adjourn

Saturday, November 20, 2010



8:00 am
Welcome to day two
Corey J. Langer, MD, FACP

Session VI: Advanced NSCLC

8:05 am
Pre-activity knowledge/confidence assessment of the audience via ARS survey

8:10 am
Role of histology in determining therapy in NSCLC
Chandra P. Belani, MD

8:30 am
Debate: An EGFR TKI should be used as first-choice therapy in EGFR mutation

Yes:
Lecia V. Sequist, MD, MPH

No:
Karen L. Kelly, MD

9:00 am
Has molecular determination MADe IT in 2010?
George R. Simon, MD

9:20 am
Panel discussion and post-activity knowledge/confidence assessment of the audience via ARS survey

9:40 am
Break

10:00 am
Pre-activity knowledge/confidence assessment of the audience via ARS survey

10:05 am
Debate: What is the optimal extended therapy approach?
Maintenance/consolidation versus observation

Maintenance/consolidation:
Chandra P. Belani, MD

Observation:
Tracey L. Evans, MD

10:35 am
Salvage therapy in advanced NSCLC
Barbara Gitlitz, MD

10:55 am
Elderly with advanced NSCLC: Combating therapeutic nihilism in older patients
Corey J. Langer, MD, FACP

11:15 am
Panel discussion and post-activity knowledge/confidence assessment of the audience via ARS survey

Session VII: Supportive therapy

11:30 am
Quality of life: Neglected focus in lung cancer research
Richard J. Gralla, MD

11:50 am
Controlling chemotherapy induced nausea and vomiting
Paul J. Hesketh, MD

12:10 pm
Bone metastases: Expanding options?
Vira Hirsh, MD, FRCP

12:30 pm
Panel discussion and knowledge/confidence assessment of the audience via ARS survey

12:45 pm
Lunch

Session VIII: Targeted therapies

1:30 pm
Pre-activity knowledge/confidence assessment of the audience via ARS survey

1:35 pm
Angiogenesis inhibition: Bevacizumab and beyond
Suresh S. Ramalingam, MD

1:55pm
Reversing resistance to EGFR TKIs
Vincent A. Miller, MD

2:15 pm
Promising new therapies in NSCLC
Roger B. Cohen, MD

2:40 pm
Panel discussion and post-activity knowledge/confidence assessment of the audience via ARS survey

2:55 pm
Break

Session IX: Biomarkers

3:10 pm
Pre-activity knowledge/confidence assessment of the audience via ARS survey

3:15 pm
Looking beyond EGFR mutations: The role of proteomics and other biomarker proteomics
Fred R. Hirsch, MD, PhD

3:35 pm
Personalized therapy: The future has arrived
Speaker invited

3:55 pm
Panel discussion and post-activity knowledge/confidence assessment of the audience via ARS survey

4:15 pm
Closing notes
Corey J. Langer, MD, FACP

4:20 pm
Adjourn

Kontakt: meetings@imedex.com

Web: http://www.imedex....ements/a184-01.asp

  • Sdílejte na:
    • Facebook
    • Twitter
    • Del.icio.us
    • Digg
    • Google
    • Reddit
    • StumbleUpon
    • Live

Podpora ČOS

Podpora Linkos.cz 

Děkujeme za podporu Linkos.cz! 

I my podporujeme 

Mezi členy ČOS je mnoho DOBRÝCH ANDĚLŮ, kteří přispívají rodinám, jež se vinou nemoci dostali do finanční tísně, ale také těch, kteří zprostředkují pomoc nadace DOBRÝ ANDĚL svým pacientům.